Organo (6368) Q1 2027 earnings summary

Executive summary

• Orders received surged 85.0% year-over-year to ¥110,235 million, driven by large-scale semiconductor projects and robust maintenance demand.

• Net sales rose 10.7% year-over-year to ¥42,183 million, while operating profit declined 4.9% to ¥6,612 million due to lower gross margins and higher SG&A expenses.

• Profit attributable to owners of parent decreased 5.7% year-over-year to ¥3,436 million.

• Order backlog as of June 30, 2026, increased 34.6% year-over-year to ¥165,132 million.

Financial highlights

• Net sales: ¥42,183 million (+10.7% YoY); Operating profit: ¥6,612 million (−4.9% YoY); Ordinary profit: ¥6,762 million (+4.5% YoY); Net income: ¥3,436 million (−5.7% YoY).

• Gross profit margin declined due to absence of high-margin projects and increased SG&A expenses.

• Basic EPS: ¥74.73 (vs. ¥79.25 last year).

• Comprehensive income: ¥3,759 million (+48.6% YoY).

Outlook and guidance

• Full-year forecast: Net sales ¥200,000 million (+12.6% YoY), operating profit ¥40,000 million (+6.2% YoY), net income ¥30,000 million (+5.6% YoY).

• Orders received forecast revised upward to ¥170,000 million for H1 (+30.8% vs. previous forecast) and ¥300,000 million for full year (+30.4%).

• No change to net sales or profit forecasts for the current fiscal year; impact of higher orders expected from next fiscal year.

• Basic EPS forecast for FY27: ¥130.48 (¥652.42 excluding share split impact).